Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Sponsor: The George Institute
Summary
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
994
Start Date
2023-01-01
Completion Date
2026-06-30
Last Updated
2024-12-20
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin
SGLT2 inhibitor
Metformin
Metformin
Locations (8)
The George Institute for Global Health
Sydney, New South Wales, Australia
The George Institute for Global Health
Brisbane, Queensland, Australia
Monash University
Melbourne, Victoria, Australia
National Hospital - Galle
Galle, Southern Province, Sri Lanka
National Hospital of Sri Lanka 1
Colombo, Sri Lanka
National Hospital of Sri Lanka 2
Colombo, Sri Lanka
Jaffna Teaching Hospital
Jaffna, Sri Lanka
Kandy National Hospital
Kandy, Sri Lanka